Check out this SlideShare Presentation:
Thursday, February 18, 2010
Thursday, December 10, 2009
Recombinant Factor VIIa
INDICATIONS: Treatment of bleeding in Hemophilia patients.
LIKELY TO BE OF BENEFIT IN : Patients with thrombocytopenia, Functional platelet defects, Surgical bleeding situations with dilutional or consumptive coagulopathies , Patients with impaired liver function.
MECHANISM OF ACTION : Enhance thrombin generation on activated platelets.
DOSE : 70-90 microgram/Kg OR on a non-weight basis- 4.8 mg vial to an adult [50-100 kg wt]
CLINICAL SITUATIONS :Patients receiving anticoagulant therapy : to reverse the effect of warfarin and other vitamin K antagonists, especially when treatment with vit-K alone has been found to be insufficient. DOSE - 1.2 mg or 20 microgram/ Kg
CLINICAL SITUATIONS :Patients receiving anticoagulant therapy : to reverse the effect of warfarin and other vitamin K antagonists, especially when treatment with vit-K alone has been found to be insufficient. DOSE - 1.2 mg or 20 microgram/ Kg
Patients with impaired liver function : Procedures like laparoscopic liver biopsy can be performed safely when it is contraindicated due to coagulopathy.
Patients with hemorrhagic stroke : Efficacy not clearly proven.
SIDE EFFECTS: Thrombotic complications like DVT , CVA , M.I.,Pulmonary embolism ,Arterial Thrombus , Clotted devices.
CAUTION IN: Patients with history of thrombotic complications , factor V Leiden , antiphospholipid syndrome , excessive bleeding in the setting of DIC, situations where there is generalised activation of the coagulation system e.g. Patients on ECMO and Ventricular Assist Devices.
AVOID IN: Patients being treated with activated Prothrombin complex.
Sunday, November 1, 2009
Sunday, October 18, 2009
Monday, October 12, 2009
Friday, October 9, 2009
Subscribe to:
Posts (Atom)